C M Surawicz

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease
    Lynne V McFarland
    Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, USA
    Am J Gastroenterol 97:1769-75. 2002
  2. ncbi Treatment of recurrent Clostridium difficile-associated disease
    Christina M Surawicz
    University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA
    Nat Clin Pract Gastroenterol Hepatol 1:32-8. 2004
  3. ncbi Pseudomembranous colitis: causes and cures
    C M Surawicz
    University of Washington, Seattle, Wash, USA
    Digestion 60:91-100. 1999
  4. ncbi [The microbiota and infectious diarrhea]
    C M Surawicz
    University of Washington School of Medicine, 325 9th Avenue, Seattle, WA 98104, USA
    Gastroenterol Clin Biol 34:S29-36. 2010
  5. ncbi Mechanisms of diarrhea
    Christina M Surawicz
    Division of Gastroenterology, Department of Medicine, School of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, Box 359773, Seattle, WA 98104, USA
    Curr Gastroenterol Rep 12:236-41. 2010
  6. ncbi Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea
    Christina M Surawicz
    University of Washington SOM, Seattle, WA 98104, USA
    J Clin Gastroenterol 42:S64-70. 2008
  7. ncbi Treatment of refractory and recurrent Clostridium difficile infection
    Christina M Surawicz
    Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 325 Ninth Avenue, Box 359773, Seattle, WA 98104, USA
    Nat Rev Gastroenterol Hepatol 8:330-9. 2011
  8. ncbi Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?
    Christina M Surawicz
    Department of Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Chemotherapy 51:81-9. 2005
  9. ncbi Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans
    Christina M Surawicz
    Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Best Pract Res Clin Gastroenterol 17:775-83. 2003
  10. ncbi The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii
    C M Surawicz
    Division of Gastroenterology, Department of Medicine, University of Washoington, Seattle, WA USA
    Clin Infect Dis 31:1012-7. 2000

Collaborators

Detail Information

Publications24

  1. ncbi Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease
    Lynne V McFarland
    Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, USA
    Am J Gastroenterol 97:1769-75. 2002
    ..The persistence of C. difficile spores suggests that additional strategies to restore the normal colonic microflora may also be beneficial...
  2. ncbi Treatment of recurrent Clostridium difficile-associated disease
    Christina M Surawicz
    University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA
    Nat Clin Pract Gastroenterol Hepatol 1:32-8. 2004
    ..In addition, there are numerous new treatment approaches that are under development, including a vaccine, which promise to aid the future treatment of RCDAD as well as prevention of initial CDAD...
  3. ncbi Pseudomembranous colitis: causes and cures
    C M Surawicz
    University of Washington, Seattle, Wash, USA
    Digestion 60:91-100. 1999
    ..The yeast Saccharomyces boulardii has been proven in controlled trials to reduce recurrences when given as an adjunct to antibiotic therapy. Careful hand washing and environmental decontamination are necessary to prevent epidemics...
  4. ncbi [The microbiota and infectious diarrhea]
    C M Surawicz
    University of Washington School of Medicine, 325 9th Avenue, Seattle, WA 98104, USA
    Gastroenterol Clin Biol 34:S29-36. 2010
    ..It is likely that we will learn even more in the future about the beneficial effect of our microbiota...
  5. ncbi Mechanisms of diarrhea
    Christina M Surawicz
    Division of Gastroenterology, Department of Medicine, School of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, Box 359773, Seattle, WA 98104, USA
    Curr Gastroenterol Rep 12:236-41. 2010
    ..Understanding such basic mechanisms may lead to better and novel therapies for treatment of diarrhea...
  6. ncbi Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea
    Christina M Surawicz
    University of Washington SOM, Seattle, WA 98104, USA
    J Clin Gastroenterol 42:S64-70. 2008
    ..difficile diarrhea is reviewed. Various probiotics have variable efficacy. More studies are needed to define further their efficacies, roles, and indications...
  7. ncbi Treatment of refractory and recurrent Clostridium difficile infection
    Christina M Surawicz
    Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 325 Ninth Avenue, Box 359773, Seattle, WA 98104, USA
    Nat Rev Gastroenterol Hepatol 8:330-9. 2011
    ..Treatments include antibiotics, adjunct probiotics, fecal microbiota transplant and immune approaches. This Review discusses the various therapeutic approaches used for the treatment of refractory and recurrent CDI...
  8. ncbi Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?
    Christina M Surawicz
    Department of Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Chemotherapy 51:81-9. 2005
    ..Controlled trials would prove this but are not yet available. Probiotics may be a good adjunct to poorly absorbed antibiotics to minimize the risk of diarrhea associated with antibiotics...
  9. ncbi Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans
    Christina M Surawicz
    Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Best Pract Res Clin Gastroenterol 17:775-83. 2003
    ..Additional controlled trials and safety studies are needed before there can be a widespread endorsement of probiotics for these two conditions...
  10. ncbi The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii
    C M Surawicz
    Division of Gastroenterology, Department of Medicine, University of Washoington, Seattle, WA USA
    Clin Infect Dis 31:1012-7. 2000
    ..Comparison of data from this trial with data from previous studies indicates that recurrent CDD may respond to a short course of high-dose vancomycin or to longer courses of low-dose vancomycin when either is combined with S. boulardii...
  11. ncbi Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients
    G W Elmer
    Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle 98195, USA
    Aliment Pharmacol Ther 13:1663-8. 1999
    ..The present study reports the stool concentrations of Saccharomyces boulardii in a patient population with Clostridium difficile disease (CDD) and correlates stool concentrations with efficacy...
  12. ncbi Treatment strategies for C. difficile associated diarrhea
    Crenguta Stepan
    University of Washington, Seattle, USA
    Acta Gastroenterol Latinoam 37:183-91. 2007
    ..Prevention is also very important in controlling this disease: first by limiting the use of broad spectrum antibiotics and secondly by controlling the environmental spreading through gloves, handwashing and disposable thermometers...
  13. ncbi Probiotics in the prevention and treatment of gastrointestinal infections
    Elizabeth S Huebner
    Division of Gastroenterology, University of Washington School of Medicine, Box 356424, 1959 NE Pacific Street, Seattle, WA 98195-6424, USA
    Gastroenterol Clin North Am 35:355-65. 2006
    ..Additional clinical trials are indicated to define the role of probiotics further before wide-spread use can be recommended...
  14. ncbi Evolving concepts in Clostridium difficile colitis
    Naomi G Diggs
    Department of Medicine, Division of Gastroenterology, University of Washington School of Medicine, Harborview Medical Center, Seattle, WA 98104, USA
    Curr Gastroenterol Rep 11:400-5. 2009
    ..With increasing incidence and severity of disease, the need for improved diagnostic, treatment, and infection control strategies cannot be overstated...
  15. ncbi Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea
    Crenguta Stepan
    University of Washington, Gastroenterology, Harborview Medical Center, 325 9th Avenue, Box 359773 Seattle, WA 98104, USA
    Expert Rev Gastroenterol Hepatol 1:295-305. 2007
    ..Treatment of refractory and recurrent CDAD remain therapeutic challenges. Improved treatments are needed; several new drugs are currently in trials...
  16. ncbi Probiotics and prebiotics in clinical practice
    Elizabeth K Broussard
    Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington 98104, USA
    Nutr Clin Care 7:104-13. 2004
    ..Rather than introducing exogenous bacteria into the intestinal millieu, prebiotics stimulate certain indigenous bacteria already resident in the gut...
  17. ncbi Clinical correlation of toxin and common antigen enzyme immunoassay testing in patients with Clostridium difficile disease
    Scott D Lee
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Am J Gastroenterol 98:1569-72. 2003
    ..When both common antigen and toxin A are positive, the likelihood of C. difficile diarrhea is high; conversely, when both results are negative, the likelihood of C. difficile diarrhea is low...
  18. ncbi Maintenance infliximab infusions forever?
    Scott D Lee
    University of Washington, Seattle, USA
    Am J Gastroenterol 97:2917-8. 2002
  19. ncbi Emerging infections of the gastrointestinal tract
    Christine Schlenker
    Division of Gastroenterology, Department of Medicine, University of Washington, School of Medicine, Seattle, WA 98104, USA
    Best Pract Res Clin Gastroenterol 23:89-99. 2009
    ..Helicobacteria are reviewed, as well as the role of gastric acid suppression in predisposing to enteric infections...
  20. ncbi Chronic diarrhea
    Peggy D Headstrom
    Department of Gastroenterology, University of Washington, Seattle, Washington, USA
    Clin Gastroenterol Hepatol 3:734-7. 2005
  21. ncbi The changing face of Clostridium difficile: what treatment options remain?
    Edie P Shen
    Am J Gastroenterol 102:2789-92. 2007
    ..difficile-associated diarrhea (CDAD). This editorial explores these, particularly in complicated cases and high-risk populations...
  22. ncbi Antibiotics and Clostridium difficile: cause and cure
    Christina M Surawicz
    J Clin Gastroenterol 41:1-2. 2007
  23. ncbi Clostridium difficile infection
    Ernst J Kuipers
    Departments of Gastroenterology and Hepatology, and Internal Medicine, Erasmus MC University Medical Center, 3000 CA Rotterdam, Netherlands
    Lancet 371:1486-8. 2008
  24. ncbi Antibiotic-associated diarrhea in children: how many dirty diapers?
    Christina M Surawicz
    J Pediatr Gastroenterol Nutr 37:2-3. 2003